CM Venture Capital Exclusively Leads Pre-A+ Round in BOEA·WISDOM to Advance Precision Cardiovascular Care

03/24/2026

CM Venture Capital, a sciencedriven venture capital firm, has exclusively led a multi-million-yuan Pre-A+ round of financing in BOEA·WISDOM Technology Co., Ltd. (BOEA·WISDOM). The funds will be used to accelerate core product R&D, expand multi-center clinical trials, advance commercialization, and strengthen the team—further solidifying the company’s technological leadership in precision interventional vascular solutions.

From Overseas Labs to a Mission-Driven Startup

The company’s journey began in 2019, when a late-night call from a leading vascular surgeon in China reached a group of overseas-based researchers. Despite holding top-tier patents and established careers abroad, the team was moved by the urgent need for more precise cardiovascular diagnostics and treatment in China.

They returned home to found BOEA·WISDOM—"BOEA" echoing "boys," reflecting the founders’ youthful passion, and "WISDOM" representing their commitment to technology-enabled care. Based in Hangzhou, the company integrates engineering simulation, artificial intelligence, and clinical medicine to transform cardiovascular intervention.

Key Milestones

  • June 2019: Company established in Hangzhou.
  • January 2022: Completed Pre-A round financing.
  • November 2023: Received China’s first NMPA Class III medical device certificate for an interventional vascular surgical planning software; launched the core product, DetecMicro®
  • July 2024: Completed the first hospital deployment (the Third Affiliated Hospital of Jilin University), marking initial commercial traction.
  • 2025: Expanded to five benchmark hospitals; formed strategic partnerships

    with Medtronic, Siemens, GE, and other industry leaders; launched a vascular interventional device implantation simulation software and initiated clinical validation with Academician Wang Jian’an’s team.

BOEA·WISDOM’s platform leverages computational fluid dynamics (CFD), computational solid mechanics (CSM), and AI-powered digital twin technology to build patient-specific vascular models. It offers a full-process solution covering imaging, preoperative planning, intraoperative navigation, and postoperative monitoring. By collaborating with leading tertiary hospitals, the company aims to make complex vascular interventions safer and more precise, advancing personalized and intelligent cardiovascular care.

Investor Perspective

CM Venture Capital, the lead investor in this round, is a science-driven venture capital firm deeply rooted in transformative hard tech. Since 2010, it has been active in China’s technology investment landscape, focusing on cutting-edge sectors such as materials and resources, energy and power, as well as digitalization and AI+. Leveraging the expertise of its multinational scientist team, global industrial resources, and a disciplined investment philosophy, CM Venture Capital is consistently committed to providing both capital and strategic support to hard tech businesses

The firm connected with BOEA·WISDOM through a partnership with L’Oréal, where BOEA won the 2024 Big Bang Award for its AI-powered simulation technology. Traditional simulation is time-consuming and computationally heavy, especially for cardiovascular applications. BOEA’s core platform, rooted in a “reactive force simulation” principle developed since 2007, features fully self-developed code and delivers faster, more efficient simulations. This opens new commercial opportunities across consumer, industrial, and healthcare applications. In cardiovascular precision care, a field with urgent clinical needs and strong market potential, BOEA’s proprietary technology has earned recognition from partners such as Siemens and Medtronic. CM Venture Capital will continue to provide capital and strategic support to help BOEA expand its medical and, in due course, non-medical applications.

Looking Ahead

This funding marks a new chapter for BOEA·WISDOM. The company will continue to deepen its focus on interventional vascular precision solutions, advancing its Detec, Medi, and vascular simulation quality control product lines. On the technology front, it will refine simulation algorithms and digital twin capabilities to expand accuracy and application scope into peripheral vascular and neurointerventional fields. On the commercial front, it will accelerate nationwide multi-center clinical adoption and strengthen partnerships with medical institutions and industry players.

With a steadfast commitment to innovation and purpose, BOEA·WISDOM aims to become a global leader in digital simulation for cardiovascular care, bringing life-saving precision to patients and clinicians alike.